BlackRock’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.14B | Sell |
7,622,935
-3,930,824
| -34% | -$428M | 0.02% | 685 |
|
|
2026
Q1 | $1.07B | Buy |
11,553,759
+236,045
| +2% | +$23.7M | 0.02% | 664 |
|
|
2025
Q4 | $1.16B | Sell |
11,317,714
-111,601
| -1% | -$9.98M | 0.02% | 627 |
|
|
2025
Q3 | $714M | Buy |
11,429,315
+449,845
| +4% | +$24.5M | 0.01% | 853 |
|
|
2025
Q2 | $571M | Sell |
10,979,470
-194,410
| -2% | -$8.68M | 0.01% | 968 |
|
|
2025
Q1 | $476M | Sell |
11,173,880
-527,707
| -5% | -$22.8M | 0.01% | 1078 |
|
|
2024
Q4 | $357M | Buy |
11,701,587
+266,023
| +2% | +$7.48M | 0.01% | 1308 |
|
|
2024
Q3 | $262M | Buy |
11,435,564
+197,708
| +2% | +$5.6M | 0.01% | 1493 |
|
|
2024
Q2 | $325M | Buy |
11,237,856
+223,924
| +2% | +$5.21M | 0.01% | 1295 |
|
|
2024
Q1 | $227M | Buy |
11,013,932
+182,216
| +2% | +$3.91M | 0.01% | 1564 |
|
|
2023
Q4 | $293M | Buy |
10,831,716
+829,157
| +8% | +$21.8M | 0.01% | 1384 |
|
|
2023
Q3 | $296M | Buy |
10,002,559
+325,038
| +3% | +$11.4M | 0.01% | 1280 |
|
|
2023
Q2 | $346M | Buy |
9,677,521
+3,782,191
| +64% | +$109M | 0.01% | 1183 |
|
|
2023
Q1 | $138M | Buy |
5,895,330
+399,865
| +7% | +$11.4M | ﹤0.01% | 1816 |
|
|
2022
Q4 | $149M | Buy |
5,495,465
+227,304
| +4% | +$10.4M | ﹤0.01% | 1731 |
|
|
2022
Q3 | $284M | Buy |
5,268,161
+60,433
| +1% | +$3.1M | 0.01% | 1213 |
|
|
2022
Q2 | $210M | Buy |
5,207,728
+106,920
| +2% | +$5.3M | 0.01% | 1489 |
|
|
2022
Q1 | $338M | Sell |
5,100,808
-9,422
| -0.2% | -$645K | 0.01% | 1262 |
|
|
2021
Q4 | $511M | Sell |
5,110,230
-445,768
| -8% | -$46.1M | 0.01% | 1010 |
|
|
2021
Q3 | $695M | Buy |
5,555,998
+30,319
| +0.5% | +$3.6M | 0.02% | 752 |
|
|
2021
Q2 | $686M | Buy |
5,525,679
+121,224
| +2% | +$16.3M | 0.02% | 797 |
|
|
2021
Q1 | $825M | Buy |
5,404,455
+80,514
| +2% | +$12.2M | 0.02% | 681 |
|
|
2020
Q4 | $686M | Buy |
5,323,941
+338,191
| +7% | +$38.9M | 0.02% | 694 |
|
|
2020
Q3 | $557M | Buy |
4,985,750
+411,884
| +9% | +$37.7M | 0.02% | 691 |
|
|
2020
Q2 | $371M | Buy |
4,573,866
+1,554,140
| +51% | +$125M | 0.01% | 901 |
|
|
2020
Q1 | $210M | Buy |
3,019,726
+161,464
| +6% | +$12.4M | 0.01% | 1128 |
|
|
2019
Q4 | $223M | Buy |
2,858,262
+914,789
| +47% | +$65.9M | 0.01% | 1400 |
|
|
2019
Q3 | $124M | Sell |
1,943,473
-312,336
| -14% | -$27.5M | 0.01% | 1763 |
|
|
2019
Q2 | $195M | Buy |
2,255,809
+1,122,983
| +99% | +$85.8M | 0.01% | 1456 |
|
|
2019
Q1 | $86.9M | Buy |
1,132,826
+18,315
| +2% | +$1.02M | ﹤0.01% | 1956 |
|
|
2018
Q4 | $41.9M | Buy |
+1,114,511
| New | +$41.1M | ﹤0.01% | 2341 |
|
Other funds holding GH
DTC
BlackRock's GH Position: Q2 2026 in Review
BlackRock reduced its Guardant Health (GH) stake by 34% in Q2 2026, selling an estimated $428M and leaving 7,622,935 shares worth $1.14B. The position accounts for 0.02% of the portfolio, ranked #685.
BlackRock first reported a position in GH in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.16B in Q4 2025. 596 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- BlackRock held 7,622,935 shares of Guardant Health worth $1.14B as of Q2 2026.
- BlackRock sold 3,930,824 Guardant Health shares in Q2 2026, an estimated $428M.
- Guardant Health made up 0.02% of BlackRock's portfolio in Q2 2026, its #685 holding.
- BlackRock first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
- BlackRock's Guardant Health position peaked at $1.16B in Q4 2025.
- 596 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.